학술논문
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Document Type
Article
Author
Ahn, Inhye E.; Brander, Danielle M.; Ren, Yue; Zhou, Yinglu; Tyekucheva, Svitlana; Walker, Heather A.; Black, Robert; Montegaard, Josie; Alencar, Alvaro; Shune, Leyla; Omaira, Mohammad; Jacobson, Caron A.; Armand, Philippe; Ng, Samuel Y.; Crombie, Jennifer; Fisher, David C.; LaCasce, Ann S.; Arnason, Jon; Hochberg, Ephraim P.; Takvorian, Ronald W.; Abramson, Jeremy S.; Brown, Jennifer R.; Davids, Matthew S.
Source
In Blood Advances 27 February 2024 8(4):832-841
Subject
Language
ISSN
2473-9529